Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis LR Kisley, BS Barrett, AK Bauer, LD Dwyer-Nield, B Barthel, AM Meyer, ... Cancer research 62 (23), 6850-6856, 2002 | 170 | 2002 |
Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases DJ Burkhart, BL Barthel, GC Post, BT Kalet, JW Nafie, RK Shoemaker, ... Journal of medicinal chemistry 49 (24), 7002-7012, 2006 | 61 | 2006 |
Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs D Xiao, D Shi, D Yang, B Barthel, TH Koch, B Yan Biochemical pharmacology 85 (3), 439-447, 2013 | 55 | 2013 |
Doxazolidine, a proposed active metabolite of doxorubicin that cross-links DNA GC Post, BL Barthel, DJ Burkhart, JR Hagadorn, TH Koch Journal of medicinal chemistry 48 (24), 7648-7657, 2005 | 51 | 2005 |
Synthesis and biological characterization of protease-activated prodrugs of doxazolidine BL Barthel, DL Rudnicki, TP Kirby, SM Colvin, DJ Burkhart, TH Koch Journal of medicinal chemistry 55 (14), 6595-6607, 2012 | 46 | 2012 |
Identification of human intestinal carboxylesterase as the primary enzyme for activation of a doxazolidine carbamate prodrug BL Barthel, RC Torres, JL Hyatt, CC Edwards, MJ Hatfield, PM Potter, ... Journal of medicinal chemistry 51 (2), 298-304, 2008 | 42 | 2008 |
Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine BL Barthel, Z Zhang, DL Rudnicki, CD Coldren, M Polinkovsky, H Sun, ... Journal of medicinal chemistry 52 (23), 7678-7688, 2009 | 41 | 2009 |
Anthracycline–Formaldehyde Conjugates and Their Targeted Prodrugs TH Koch, BL Barthel, BT Kalet, DL Rudnicki, GC Post, DJ Burkhart Anthracycline Chemistry and Biology II: Mode of action, clinical aspects and …, 2008 | 23 | 2008 |
Leveraging colloidal aggregation for drug-rich nanoparticle formulations AN Ganesh, J Logie, CK McLaughlin, BL Barthel, TH Koch, BK Shoichet, ... Molecular pharmaceutics 14 (6), 1852-1860, 2017 | 21 | 2017 |
Correlation of in situ oxazolidine formation with highly synergistic cytotoxicity and DNA cross-linking in cancer cells from combinations of doxorubicin and formaldehyde BL Barthel, EL Mooz, LE Wiener, GG Koch, TH Koch Journal of Medicinal Chemistry 59 (5), 2205-2221, 2016 | 18 | 2016 |
Large increases in plasma fast skeletal muscle troponin I after whole-body eccentric exercises TC Chen, HW Liu, A Russell, BL Barthel, KW Tseng, MJ Huang, TY Chou, ... Journal of Science and Medicine in Sport 23 (8), 776-781, 2020 | 16 | 2020 |
Elevation of fast but not slow troponin I in the circulation of patients with Becker and Duchenne muscular dystrophy BL Barthel, D Cox, M Barbieri, M Ziemba, V Straub, EP Hoffman, ... Muscle & Nerve 64 (1), 43-49, 2021 | 14 | 2021 |
Methods of treating cancer with doxazolidine and prodrugs thereof TH Koch, DJ Burkhart, GC Post, JW Nafie, BT Kalet, BL Barthel, ... US Patent 8,404,650, 2013 | 9 | 2013 |
Modulating fast skeletal muscle contraction protects skeletal muscle in animal models of Duchenne muscular dystrophy AJ Russell, M DuVall, B Barthel, Y Qian, AK Peter, BL Newell-Stamper, ... The Journal of clinical investigation 133 (10), 2023 | 6 | 2023 |
P. 124 EDG-5506 targets fast skeletal myosin and reduces muscle damage biomarkers in a phase 1 trial in Becker muscular dystrophy (BMD) J Donovan, N Kilburn, G Gordon, B Barthel, M DuVall, A Bronson, ... Neuromuscular Disorders 32, S100, 2022 | 3 | 2022 |
Direct and selective myosin-inhibition stabilizes the super-relaxed state of myosin and blunts post-tetanic potentiation in fast-skeletal muscle B Stamper, S Lehman, M Madden, M DuVall, Y Qian, M Evanchik, ... Biophysical Journal 121 (3), 515a-516a, 2022 | 1 | 2022 |
EDG-5506 is a Selective Inhibitor of Fast Skeletal Muscle Myosin M DuVall, M Madden, B Barthel, S Lehman, HL Sweeney, AJ Russell Edgewise Therapeutics, 2022 | 1 | 2022 |
Effects of EDG-5506, a Fast Myosin Modulator, on Function and Biomarkers of Muscle Damage in Adults with Becker Muscular Dystrophy (S21. 002) H Phan, S Collins, A Russell, B Barthel, L Thaler, N Kilburn, M Mancini, ... Neurology 102 (17_supplement_1), 6037, 2024 | | 2024 |
P255 Effects of EDG-5506, a fast myosin modulator, on function and biomarkers of muscle damage in adults with Becker muscular dystrophy (BMD) S Collins, H Phan, A Russell, B Barthel, L Thaler, N Kilburn, M Mancini, ... Neuromuscular Disorders 33, S146-S147, 2023 | | 2023 |
P254 Characterization of short-and long-term proteomic response to the fast skeletal myosin inhibitor, EDG-5506, in Becker muscular dystrophy (BMD) B Barthel, M Madden, L Thaler, M Evanchik, K Koch, J Donovan, S Collins, ... Neuromuscular Disorders 33, S146, 2023 | | 2023 |